Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

Abstract

Capucine Baldini, Stéphane Champiat, Perrine Vuagnat, Christophe Massard Drug Development Department, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France Abstract: Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression Keywords: immunotherapy, PD-L1 inhibitor, durvalumab, urothelial carcinoma, bladder cancer

Keywords

• Immunotherapy
• PD-L1 inhibitor
• Durvalumab
• Urothelial carcinoma
• Bladder cancer